A robotic puppy with a 23,000-name waitlist raised $7M to start shipping

The interesting number in Tombot's raise is not the $7 million. It is the 23,000 people who put down their names for a robotic Labrador before the first unit shipped. That waitlist is the asset, and the financing exists to turn it into revenue by fall.

Tombot closes a $7M Series A3 to move from development to shipping

The companion-robotics maker closed a $7 million Series A3 growth round. Investors include Caduceus Capital Partners, Wavemaker 360, the Lutheran Foundation for Long Term Living, and Florida Community Health Network.

The money funds the transition from product development to commercial scale: manufacturing, operations, and a planned first customer shipment in fall 2026.

Tombot's product, Jennie, is a robotic puppy built to mimic the movement and responses of an 8-to-10-week-old Labrador. It is aimed at older adults and people managing anxiety, loneliness, autism, or PTSD who cannot care for a live animal.

The company reports more than 23,000 pre-order and waitlist customers. Founder and chief executive Tom Stevens, who has spent more than 35 years across healthcare robotics, AI, and the pet industry, framed the round as the bridge from building to selling. The idea traces back to his own mother's experience.

Why the investor mix matters more than the round size

Look at who wrote the checks. This is not a consumer-gadget syndicate. Caduceus and Wavemaker 360 are healthcare-focused, and the other two backers are long-term-care and community-health institutions. That tells you what Tombot actually is.

This is a healthcare play wearing a pet-industry costume

Jennie competes less with toys and more with companionship interventions in elder care, memory care, and behavioral health. The backers are positioning it for institutional channels, senior living, and aging-in-place, where reimbursement and bulk purchasing live.

A 23,000-name waitlist de-risks the launch and tells you about demand

Pre-orders at this scale are rare validation for hardware, which usually struggles to prove appetite before tooling. It also explains a $7 million round that is sized to manufacture and ship, not to keep searching for product-market fit.

The pet-adjacent framing is a wedge, not the market

The lesson for operators: the companionship value of pets is being unbundled from live animals. That opens categories live pets cannot serve, from allergy and mobility constraints to facilities that ban animals. The emotional job-to-be-done travels even when the dog does not.

The risk is the oldest one in hardware. A waitlist is not a sale, and manufacturing at scale has killed more well-funded robotics companies than weak demand ever did. Fall shipping is the moment the 23,000 names either convert or churn.

Whether the fall launch converts the waitlist into a business

The next two quarters are the whole test. Watch three things.

Conversion: how many of the 23,000 actually buy when invoiced, and at what price point. That ratio is the real demand signal.

Channel: whether Tombot sells direct to consumers, into senior-living and care facilities, or both. The institutional path is slower but stickier and points back to its healthcare investors.

Unit economics: robotic hardware lives or dies on bill-of-materials and returns. A companion device that disappoints emotionally gets sent back fast.

Ship dates slip. If Tombot hits fall and converts even a fraction of its waitlist, it proves a category thesis worth watching: companionship as a product, sold on the strength of the bond pets created.

Source: Tombot Series A3 via Business Wire